New NMD4C Opportunities Page
The NMD4C is pleased to announce the most recent addition to our website – the Opportunities page!
By hosting a centralized list of neuromuscular-related opportunities, we hope to provide meaningful options to further engage in the field of NMD and provide a platform for our members to share openings with others in our community.
As a part of our ongoing commitment to support and empower the Early Career neuromuscular community, we will distinguish between opportunities for the entirety of our membership and those that are targeted towards the Early Career group by listing these on the early career page.
If you or your organization would like to share an opportunity the clinicians, researchers, allied health professionals and advocates by having us host it on our site, please reach out to us at .
Return to the February 2021 Newsletter
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.